Appln. No.: 10/571,405 Group Art Unit No.: 1624

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-8 (Canceled).

9. (Previously presented): A compound of formula (I):

wherein:

 R^{1} represents - C_{1-6} alkyl substituted by 1, 2, or 3 halogen or cyano groups; - C_{0-4} alkyl- C_{3-8} cycloalkyl; - C_{2-4} alkyl-oxy- C_{1-4} alkyl; - C_{1-4} alkyl-aryl, wherein said cycloalkyl or aryl groups of R^{1} may be optionally substituted by 1, 2, or 3 groups selected from halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino and trifluoromethyl;

 R^2 represents hydrogen or $C_{1\text{-}6}$ alkyl;

m represents 1;

R³ represents hydrogen, methyl or halogen;

R⁴ and R⁵ independently represent hydrogen or methyl;

n represents 1;

p represents 1 or 2;

A represents phenyl optionally substituted by a halogen, cyano, trifluoromethyl, or trifluoromethoxy group;

or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

Appln. No.: 10/571,405 Group Art Unit No.: 1624

- 10. (Previously presented): The compound according to claim 9, wherein: A is unsubstituted phenyl.
 - 11. (Previously presented): A compound which is:
- 8-(4-(4-Fluorobenzyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;
- 8-(4-Cyclopropylmethyl-piperazin-1-yl)-3-phenylsulfonylquinoline;
- 8-(4-(Cyclohexyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;
- 8-(4-Cyclopentyl-piperazin-1-yl)-3-phenylsulfonylquinoline;
- 8-(4-Cyclobutyl-piperazin-1-yl)-3-phenylsulfonylquinoline;
- 8-(4-Cyclopropyl-piperazin-1-yl)-3-phenylsulfonylquinoline;
- 8-(4-(2-methoxyethyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;
- 8-(4-(2,2,2-Trifluoroethyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;

or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

- 12. (Previously presented): A pharmaceutical composition which comprises the compound, salt, or hydrate according to claim 9 and a pharmaceutically acceptable carrier or excipient.
- 13. (Previously presented): A pharmaceutical composition which comprises the compound, salt, or hydrate according to claim 11 and a pharmaceutically acceptable carrier or excipient.
- 14. (Previously presented): A method of treating a cognitive memory disorder which comprises administering a therapeutically effective amount of the compound, salt, or hydrate according to claim 9 to a patient in need thereof, wherein the cognitive memory disorder is selected from age related cognitive decline, mild cognitive impairment, and cognitive deficits in schizophrenia.
- 15. (Previously presented): A method of treating a cognitive memory disorder which comprises administering a therapeutically effective amount of the compound, salt, or hydrate according to claim 11 to a patient in need thereof, wherein the cognitive memory disorder is selected from age related cognitive decline, mild cognitive impairment, and cognitive deficits in schizophrenia.

Appln. No.: 10/571,405 Group Art Unit No.: 1624

16. (Previously presented): A method of treating depression or anxiety which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.

- 17. (Previously presented): A method of treating depression or anxiety which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 11.
- 18. (Previously presented): A method of treating obesity which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.
- 19. (Previously presented): A method of treating obesity which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 11.
- 20. (Currently amended): A method of <u>treating</u> Alzheimers disease which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.
- 21. (Previously presented): A method of treating Alzheimers disease which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 11.